SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded by Vipin Kumar Chaturvedi in May 2009 and is headquartered in La Jolla, CA.

GRI Bio Inc

GRI Bio Inc. is trending following positive Phase 2a clinical data for its IPF treatment and a recent 1-for-28 reverse stock split, which has created an exceptionally low float of approximately 500k shares. The community is sharply divided; many anticipate a significant short squeeze comparing it to prior low-float runners, while others express deep skepticism citing the company's history of frequent dilutions and management's perceived lack of trustworthiness. This ongoing debate fuels significant volatility as investors weigh scientific progress against past financial actions.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is experiencing significant upward momentum after securing a pivotal U.S. Air Force contract for advanced swarming capabilities and raising its 2026 revenue guidance. The community is actively discussing the burgeoning defense AI narrative and intense short squeeze potential, driving speculative interest in this autonomous systems innovator.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is facing intense downward pressure, driven by recent analyst downgrades and widespread community belief that the stock is being manipulated for accumulation. While many investors express extreme frustration with its "PainPal" performance despite consistent earnings, substantial share buybacks, and strategic moves into AI commerce and global payments, others view the current valuation as a "criminally undervalued" long-term opportunity, setting high stakes for its next financial disclosure.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending after announcing a $75 million direct offering to a new institutional investor, effectively de-risking its Phase 3 MASH trial funding and igniting community debate. Many view this as a strategic move that strengthens negotiating leverage for a potential buyout, especially given Barclays' recent 'Overweight' rating and coverage initiation. However, some investors are concerned about dilution and the offering price, even as discussions highlight pemvidutide's 'best-in-class' profile in the competitive MASH market.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending amid a strong rally in partner company Redwire, intensifying speculation around imminent government AI contracts for defense and border security. Investors are actively debating a pending vote to increase authorized shares, with many anticipating a significant short squeeze and drawing comparisons to Palantir's growth trajectory.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending following its latest earnings report, which highlighted record order intake and robust 2026 guidance, largely fueled by accelerating AI-related demand. The community is actively debating the company's indispensable monopoly in EUV lithography and the increased capital expenditures from major chipmakers, even amidst some discussions around high valuation and geopolitical risks. As a core semiconductor bellwether, ASML's performance remains a crucial indicator for the industry's durability in the ongoing AI and chip supercycle.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is a top discussion point following an FDA clinical hold on its RGX-111 and RGX-121 gene therapy programs due to a safety event, triggering sharp market volatility. Despite initial panic, many investors are calling the reaction an overcorrection, emphasizing that the primary value-driving programs for wet AMD and Duchenne muscular dystrophy remain unaffected. The community is actively debating the broader impact of this regulatory action on the company's prospects, especially concerning the upcoming PDUFA decision for RGX-121.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks is trending following a mixed quarterly report where increased customer traffic signals progress in its turnaround strategy, though profitability challenges persist. The community is actively debating whether growing transaction volumes can translate into sustained earnings growth amid ongoing margin pressures and competitive market dynamics. Investors are closely watching if management's initiatives, including simplified menus and store experience improvements, will drive future profitability.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending due to circulating reports of a potential merger with Automation Anywhere, which has ignited varied community reactions. This news, coupled with significant new contracts from the U.S. Army and Department of Health and Human Services, is fueling intense speculation about a potential short squeeze given the stock's high short interest and its enterprise AI market position.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T is trending following a strong fourth-quarter earnings report that surpassed expectations and provided a bullish multi-year outlook. The community is actively discussing the company's commitment to return capital to shareholders through significant buybacks and dividends, alongside continued growth in its crucial fiber and 5G businesses. Investors view AT&T as a compelling value and a defensive play, despite competitive pressures, fueled by optimism around its strategic investments in advanced connectivity and satellite partnerships.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Innovation Ltd Panacea Sells 80,554 Shares of Atara Biotherapeutics (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) major shareholder Innovation Ltd Panacea sold 80,554 shares of Atara Biotherapeutics stock in a transaction dated Monday, January 12th. The...

<ul class="summary-bullets"><li>This is the second time that the FDA has refused to approve EBVALLO.</li><li>Atara said in a statement on Monday that the FDA’s new position is “contrary” to its prior alignment with the company on the trial design.</li><li>Atara had transferred its application seeking approval for EBVALLO to a U.S. pharma unit of Pierre Fabre Laboratories in November.</li></ul>Shares of Atara Biotherapeutics, Inc. (ATRA) slumped 53% on Monday after the U.S. Food and Drug Administration refused approval for its immunotherapy EBVALLO in treating patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease.Epstein-Barr Virus (EBV)-positive Post-Transplant Lymphoproliferative Disorder (PTLD) is a serious, often life-threatening complication after organ or stem cell transplantation, characterized by uncontrolled growth of EBV-infected B-cells due to suppressed immunity, ranging from mononucleosis-like illness to aggressive lymphoma.The FDA <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.atarabio.com/news-events/press-releases/detail/380/atara-biotherapeutics-provides-regulatory-and-business">said</a> in a letter to the company that it is unable to approve its EBVALLO application in present form, stating that the trial conducted by the company is not adequate to provide evidence of effectiveness for accelerated approval. The authority also stated that the trial’s interpretability is confounded due to trial study design, conduct, and analysis.<h2 class="st-heading-2">Back-To-Back Rejection</h2>This is the second time that the FDA has refused to approve EBVALLO. The company resubmitted its application in 2025 after it was rejected the first time due to a concern with manufacturing.Atara said in a statement on Monday that the FDA’s new position is “contrary” to its prior alignment with the company on the trial design. “This prior alignment had been reached by Atara and the FDA through multiple, documented meetings held over the past five plus years,” it said. &nbsp;Atara had transferred its application seeking approval for EBVALLO to a U.S. pharma unit of Pierre Fabre Laboratories in November. Pierre will now seek a meeting with the FDA, which is expected to be granted within 45 days. The company said that it intends to urgently interact with FDA to find a path forward for EBVALLO approval with Pierre.<h2 class="st-heading-2">Company’s Reaction</h2>Atara CEO Cokey Nguyen said that the company is “surprised and disappointed” by the FDA decision.“The issues highlighted in the CRL were issues Atara and the FDA aligned on in previous reviews or communications. We had aligned with the agency to accept an Accelerated Approval and to perform a post marketing confirmatory study to support full approval. We proceeded with the BLA submission on this basis and continued all remediation efforts after the resubmission in 2025, in full reliance of the confirmation provided by the FDA,” the CEO said.Atara ended 2025 with cash, cash equivalents and short-term investments of $8.5 million after trimming down workforce by about 90% year-over-year and transitioning almost all activities and costs pertaining to EBVALLO to Pierre Fabre laboratories.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ATRA stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user expressed disappointment over the news.<stembedurl>https://www.stocktwits.com/BwesY/message/641538764</stembedurl>Yet another said that they added more shares of the company. “I am already sensing a big fight back,” they said.<stembedurl>https://www.stocktwits.com/Niddi/message/641533765</stembedurl><a href="https://stocktwits.com/symbol/ATRA">ATRA stock</a> has dropped 60% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-planet-labs-stock-gain-today/cmUad7cR4Ej">Planet Labs Stock Gained 7% Today — What Is The Swedish Military Deal About?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

ATRA Stock Nearly Halves In Value After FDA Refuses Approval For Immunotherapy: Retail Sees ‘Big Fight Back’

The Food and Drug Administration said in a letter to the company that it is unable to approve its EBVALLO application in present form, citing inadequate evidence of effectiveness for accelerated approval.

Equity

The Food and Drug Administration said in a letter to the company that it is unable to approve its EBVALLO application in present form, citing inadequate evidence of effectiveness for accelerated approval.


FDA Rejects Atara Biotherapeutics' Cell Therapy Again, Stock Sinks

Atara Biotherapeutics stock drops on FDA rejection of EBVALLO BLA for serious post-transplant complication. FDA raises new concerns.read more...

PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION

PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION PIERRE FABRE...

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO (tabelecleucel)

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six brokerages that are covering the company, MarketBeat Ratings...

Atara Biotherapeutics (NASDAQ:ATRA) CAO Sells $23,794.76 in Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) CAO Yanina Grant-Huerta sold 1,804 shares of the firm's stock in a transaction on Monday, November 17th. The stock was sold at an average...

Atara Biotherapeutics (NASDAQ:ATRA) CEO Anhco Nguyen Sells 2,915 Shares

Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) CEO Anhco Nguyen sold 2,915 shares of the company's stock in a transaction that occurred on Monday, November 17th. The shares were sold at...

Atara Biotherapeutics (NASDAQ:ATRA) Issues Quarterly Earnings Results, Beats Estimates By $0.51 EPS

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.32) EPS for the quarter, topping analysts...

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Current Price	$5.69
Prev Close	$5.56
Open	$5.59
Dividend Yield	0.00%
50-Day Moving Average	$13.27
Beta	2.30
Avg. Volume	75,400.73
PE Ratio	2.54

52-Week High	$19.15
52-Week Low	$4.20
Market Capitalization	$40.09M
EPS (Annual)	-$11.41
Price to Book	-1.09
Revenue Per Employee	$842,745.10
Enterprise Value/EBITDA	N/A

ATRA
Atara Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ATRA News

ATRAAtara Biotherapeutics Inc